Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tarsus Pharmaceuticals (TARS)
NASDAQ:TARS
Holding TARS?
Track your performance easily
TARS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.57 - $42.50
Previous Close$34.51
Volume1.21M
Average Volume (3M)787.60K
Market Cap
$1.31B
Enterprise Value$1.06B
Total Cash (Recent Filing)$323.58M
Total Debt (Recent Filing)$71.58M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Nov 06, 2024EPS Estimate
-$0.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.48
Shares Outstanding38,041,737
10 Day Avg. Volume711,600
30 Day Avg. Volume787,598
Standard Deviation0.19
R-Squared0.08
Alpha0.00762
Financial Highlights & Ratios
Price to Book (P/B)5.21
Price to Sales (P/S)15.75
Price to Cash Flow (P/CF)-22.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue19.02
Enterprise Value/Gross Profit66.91
Enterprise Value/Ebitda-10.41
Forecast
1Y Price Target
$63.33Price Target Upside83.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Tarsus Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Market PotentialA retrospective study conducted in the US suggests ~58% of patients visiting eye care clinics have collarettes, a pathognomonic sign of DB, which speaks to the size of the potential market.
Product LaunchTarsus’ launch of XDEMVY for demodex blepharitis (DB) continues to dramatically outperform expectations, proving one of the fastest non-orphan specialty pharma launches in recent memory.
Sales PerformanceXdemvy delivered strong +89% net sales growth with bottle volumes growing +66%.
Bears Say
Patient AccessConcerns about patient access have been raised by analysts who rated Xdemvy lower.
Payor CoverageIssues with payor coverage have been frequently cited by analysts who rated Xdemvy lower.
Study LimitationsResults are limited by the absence of a vehicle comparator, raising questions about future study endpoints.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
TARS FAQ
What was Tarsus Pharmaceuticals’s price range in the past 12 months?
Tarsus Pharmaceuticals lowest stock price was $12.57 and its highest was $42.50 in the past 12 months.
What is Tarsus Pharmaceuticals’s market cap?
Currently, no data Available
When is Tarsus Pharmaceuticals’s upcoming earnings report date?
Tarsus Pharmaceuticals’s upcoming earnings report date is Nov 06, 2024 which is in 3 days.
How were Tarsus Pharmaceuticals’s earnings last quarter?
Tarsus Pharmaceuticals released its earnings results on Aug 08, 2024. The company reported -$0.88 earnings per share for the quarter, beating the consensus estimate of -$0.923 by $0.043.
Is Tarsus Pharmaceuticals overvalued?
According to Wall Street analysts Tarsus Pharmaceuticals’s price is currently Undervalued.
Does Tarsus Pharmaceuticals pay dividends?
Tarsus Pharmaceuticals does not currently pay dividends.
What is Tarsus Pharmaceuticals’s EPS estimate?
Tarsus Pharmaceuticals’s EPS estimate is -$0.94.
How many shares outstanding does Tarsus Pharmaceuticals have?
Tarsus Pharmaceuticals has 38,041,737 shares outstanding.
What happened to Tarsus Pharmaceuticals’s price movement after its last earnings report?
Tarsus Pharmaceuticals reported an EPS of -$0.88 in its last earnings report, beating expectations of -$0.923. Following the earnings report the stock price went up 13.723%.
Which hedge fund is a major shareholder of Tarsus Pharmaceuticals?
Among the largest hedge funds holding Tarsus Pharmaceuticals’s share is Perceptive Advisors LLC. It holds Tarsus Pharmaceuticals’s shares valued at 35M.
---
Tarsus Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$63.33 (83.51% Upside)
$63.33 (83.51% Upside)
Blogger Sentiment
Bullish
TARS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 250.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $913.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 3.6%
Last 30 Days ▲ 3.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
106.02%
12-Months-Change
Fundamentals
Return on Equity
-75.04%
Trailing 12-Months
Asset Growth
99.47%
Trailing 12-Months
Company Description
Tarsus Pharmaceuticals
Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03, is a novel drug that targets the Demodex mite nervous system to kill the mites.
---
TARS Earnings Call
Q2 2024
0:00 / 0:00
---
TARS Stock 12 Month Forecast
Average Price Target
$63.33
▲(83.51% Upside)
Technical Analysis
Best Analysts Covering TARS
1 Year
1 Year Success Rate
9/10 ratings generated profit
1 Year Average Return
+50.18%
reiterated a buy rating 3 months ago
Copying Balaji Prasad's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +50.18% per trade.
---